AVLSA
Atlas Venture Life Science Advisors Portfolio holdings
AUM
$662M
This Quarter Return
+7.32%
1 Year Return
+6.63%
3 Year Return
+286.7%
5 Year Return
–
10 Year Return
–
AUM
$830M
AUM Growth
+$830M
(-8.4%)
Cap. Flow
-$118M
Cap. Flow
% of AUM
-14.27%
Top 10 Holdings %
Top 10 Hldgs %
95.96%
Holding
17
New
–
Increased
1
Reduced
6
Closed
–
Top Buys
| 1 |
Dyne Therapeutics
DYN
|
$10.8M |
Top Sells
| 1 |
Disc Medicine
IRON
|
$35.7M |
| 2 |
Replimune Group
REPL
|
$27.5M |
| 3 |
Kymera Therapeutics
KYMR
|
$22.2M |
| 4 |
Akero Therapeutics
AKRO
|
$21.9M |
| 5 |
Day One Biopharmaceuticals
DAWN
|
$12.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Day One Biopharmaceuticals
DAWN
$769M
| $163M | 19.62% | 7,568,317 -600,854 | -7% | -$12.9M |
|
|
2
Kymera Therapeutics
KYMR
$2.95B
| $149M | 17.99% | 5,984,736 -890,962 | -13% | -$22.2M |
|
|
3
Dyne Therapeutics
DYN
$1.92B
| $114M | 13.78% | 9,869,483 +934,581 | +10% | +$10.8M |
|
|
VIGL
4
DELISTED
Vigil Neuroscience
VIGL
| $73M | 8.79% | 5,836,874 | – | – |
|
|
5
Disc Medicine
IRON
$2.07B
| $68.9M | 8.29% | 3,461,784 -1,792,581 | -34% | -$35.7M |
|
|
JBIO
6
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $59.1M | 7.12% | 2,017,521 -310,388 | -13% | -$9.09M |
|
|
7
Replimune Group
REPL
$422M
| $57.1M | 6.87% | 2,098,300 -1,010,000 | -32% | -$27.5M |
|
|
THRD
8
DELISTED
Third Harmonic Bio
THRD
| $46.9M | 5.65% | 10,907,859 | – | – |
|
|
9
Akero Therapeutics
AKRO
$3.74B
| $32.6M | 3.92% | 594,251 -400,000 | -40% | -$21.9M |
|
10
Generation Bio
GBIO
$40.4M
| $32.5M | 3.92% | 8,278,876 | – | – |
|
|
IMA
11
ImageneBio, Inc. Common Stock
IMA
$150M
| $13.3M | 1.61% | 5,018,178 | – | – |
|
12
Xilio Therapeutics
XLO
$36.3M
| $7.42M | 0.89% | 2,759,344 | – | – |
|
|
FSTX
13
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $3.79M | 0.46% | 599,524 | – | – |
|
|
TECX
14
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $3.22M | 0.39% | 4,520,863 | – | – |
|
15
Viridian Therapeutics
VRDN
$1.5B
| $2.63M | 0.32% | 90,072 | – | – |
|
16
Spero Therapeutics
SPRO
$116M
| $1.78M | 0.21% | 1,031,160 | – | – |
|
17
Dianthus Therapeutics
DNTH
$759M
| $1.37M | 0.17% | 3,476,536 | – | – |
|